Blackstone commits $750 million to Johnson & Johnson's Phase 3 trials of retinal disease drug OLN324
JNJ•
JNJ•Blackstone Life Sciences will provide Johnson & Johnson $750 million to fund Phase 3 trials of OLN324 for wet age-related macular degeneration and diabetic macular edema, contingent on Johnson & Johnson closing its acquisition of Ollin Biosciences.
Blackstone Life Sciences funds will provide $750 million to Johnson & Johnson for Phase 3 development of investigational retinal disease treatment OLN324. The clinical program will target wet age-related macular degeneration and diabetic macular edema; early clinical results were described as encouraging.
Blackstone is entitled to regulatory and sales milestone payments, as well as single-digit royalties. The funding is contingent on Johnson & Johnson closing its acquisition of Ollin Biosciences.